BTIG Research reiterated their buy rating on shares of Senseonics (NYSEAMERICAN:SENS) in a research note released on Sunday, AnalystRatings.com reports. The brokerage currently has a $2.00 price objective on the stock.

A number of other research firms have also commented on SENS. Zacks Investment Research lowered Senseonics from a hold rating to a sell rating in a research report on Saturday, May 11th. Raymond James lowered Senseonics from an outperform rating to a market perform rating in a research report on Friday, July 5th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. Senseonics currently has a consensus rating of Hold and a consensus target price of $4.00.

NYSEAMERICAN SENS opened at $1.12 on Friday. Senseonics has a 12 month low of $1.00 and a 12 month high of $4.89.

Senseonics (NYSEAMERICAN:SENS) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The company had revenue of $4.61 million during the quarter, compared to analyst estimates of $4.53 million. The company’s revenue was up 27.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.16) earnings per share.

Several hedge funds have recently bought and sold shares of SENS. BlackRock Inc. grew its stake in shares of Senseonics by 6.1% during the 4th quarter. BlackRock Inc. now owns 6,142,950 shares of the company’s stock worth $15,910,000 after acquiring an additional 352,590 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Senseonics by 38.2% during the 4th quarter. Bank of New York Mellon Corp now owns 370,742 shares of the company’s stock worth $959,000 after acquiring an additional 102,508 shares during the period. Northern Trust Corp grew its stake in shares of Senseonics by 3.8% during the 4th quarter. Northern Trust Corp now owns 1,002,381 shares of the company’s stock worth $2,597,000 after acquiring an additional 36,328 shares during the period. Principal Financial Group Inc. grew its stake in shares of Senseonics by 78.0% during the 4th quarter. Principal Financial Group Inc. now owns 25,259 shares of the company’s stock worth $65,000 after acquiring an additional 11,071 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Senseonics by 620.3% during the 4th quarter. Bank of America Corp DE now owns 40,705 shares of the company’s stock worth $106,000 after acquiring an additional 35,054 shares during the period. Institutional investors own 30.66% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Featured Story: How Do Investors Open a Backdoor Roth IRA?

Analyst Recommendations for Senseonics (NYSEAMERICAN:SENS)

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.